Allogene Therapeutics, Inc. (ALLO) Price / Book
- 2026-09-03: Price/Book Ratio 1.56.
- 2026-06-30: Price/Book Ratio 1.65.
- 2026-03-31: Price/Book Ratio 2.14.
- 2025-12-31: Price/Book Ratio 1.07.
Historical market capitalization divided by filed shareholder equity.
- Available history
- 2018-12-31 to 2026-09-03
- Data captured
Historical Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |